Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation

BACKGROUND: EGFR mutation is a strong predictor of efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) therapy in advanced non-small cell lung cancer (NSCLC). However, around 20–30 % of EGFR-mutated cases showed no response to EGFR-TKIs, suggesting that other determina...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Hematol Oncol
Prif Awduron: Wang, Shuhang, Su, Xiaomei, Bai, Hua, Zhao, Jun, Duan, Jianchun, An, Tongtong, Zhuo, Minglei, Wang, Zhijie, Wu, Meina, Li, Zhenxiang, Zhu, Jian, Wang, Jie
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2015
Pynciau:
Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4643502/
https://ncbi.nlm.nih.gov/pubmed/26563758
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-015-0210-9
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg